PDCD1 and Hodgkins lymphoma: Anti-PD-1 antibodies such as nivolumab and pembrolizumab, that prevent PD-1 binding to its ligands, have been shown to significantly improve T cell immune response (proliferation and production of cytokines) as well as raising the response rate in patients with relapse/refractory HL (42, 43).